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SUMMARY
Background
Faecal microbiota transplantation or transfer (FMT) aims at replacing or
reinforcing the gut microbiota of a patient with the microbiota from a healthy
donor. Not many controlled or randomised studies have been published eval-
uating the use of FMT for other diseases than Clostridium difﬁcile infection,
making it difﬁcult for clinicians to decide on a suitable indication.
Aim
To provide an expert consensus on current clinical indications, applications
and methodological aspects of FMT.
Methods
Well-acknowledged experts from various countries in Europe have contributed
to this article. After literature review, consensus has been achieved by repetitive
circulation of the statements and the full manuscript among all authors with
intermittent adaptation to comments (using a modiﬁed Delphi process). Levels
of evidence and agreement were rated according to the GRADE system. Con-
sensus was deﬁned a priori as agreement by at least 75% of the authors.
Results
Key recommendations include the use of FMT in recurrent C. difﬁcile
infection characterised by at least two previous standard treatments without
persistent cure, as well as its consideration in severe and severe-complicated
C. difﬁcile infection as an alternative to total colectomy in case of early fail-
ure of antimicrobial therapy. FMT in inﬂammatory bowel diseases (IBD),
irritable bowel syndrome (IBS) and metabolic syndrome should only be
performed in research settings.
Conclusions
Faecal microbiota transplantation or transfer is a promising treatment for a
variety of diseases in which the intestinal microbiota is disturbed. For indica-
tions other than C. difﬁcile infection, more evidence is needed before more
concrete recommendations can be made.
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INTRODUCTION
Recent advances in culture-independent sequencing and
other high-throughput techniques have increased our
understanding of the role of the gastrointestinal micro-
biota in health and disease. An increasing number of
diseases are being linked to a disturbed intestinal
microbiota composition, including metabolic syndrome,
irritable bowel syndrome (IBS), inﬂammatory bowel
diseases (IBD) and extraintestinal disorders such as
neuropsychiatric diseases.1–3 As a consequence, thera-
peutic options are being tested which aim at restoring
a disturbed microbiota towards a healthy, beneﬁcial
one. In general, moderate effects can be achieved by
probiotic and prebiotic products, which increase the
number of beneﬁcial bacteria directly (probiotics) or
indirectly by providing substrate for residing beneﬁcial
bacteria (prebiotics).4–6 For more severe disturbances,
however, these measures are not sufﬁcient. Here, faecal
microbiota transfer or transplantation (FMT) provides
more powerful means to modify microbiota. It aims at
replacing or reinforcing the gut microbiota of a patient
with the microbiota from a healthy donor. As this pro-
cedure is not an actual transplantation, the term ‘faecal
microbial transfer’ is preferable. FMT is used for the
treatment of recurrent Clostridium difﬁcile infection
with efﬁcacy rates of 90% or even higher,7–11 giving
reason for hope that it might also be successful in
other diseases where disturbances of the intestinal
microbiota are involved.
There is an increasing demand from patients for
access to FMT as a treatment for various disorders
and diseases. However, not many controlled or ran-
domised studies have been published using FMT for
other indications than C. difﬁcile infection, which
makes it difﬁcult for clinicians to decide on a suitable
indication. The aim of this article is to provide an
expert consensus on current indications and method-
ological aspects of FMT for clinical application and to
provide recommendations on how to conduct clinical
studies using FMT. We will ﬁrst discuss applicable
indications of FMT, which is then followed by a sec-
tion on practicalities of the FMT procedure. As well-
conducted clinical studies are still missing in most
ﬁelds, it is important to note that most recommenda-
tions, especially in the indications section, are not evi-
dence-based yet. In addition, country-speciﬁc legal
regulations need to be considered when working with
FMT. Safety issues have been speciﬁcally discussed in
the sections on FMT in IBD (with or without concur-
rent C. difﬁcile) and in the section on route of admin-
istration. We further provide information on the
assessment of safety in the section on study design.
For a systematic review of adverse events associated
with FMT please refer to Baxter and Colville, 2016.12
METHODS
A literature review was performed by Robert-Jan Brum-
mer (RB), Jutta Keller (JKe), Julia K€onig (JK) and Arno
Siebenhaar using PubMed and MEDLINE using search
terms based on ‘Faecal microbiota transplantation’ (Data
S1) to identify studies that assessed the effect of FMT on
various indications and/or practicalities of the FMT pro-
cedure. Based on these, the ﬁrst draft of statements and
comments was developed. The draft was then circulated
among all co-authors for a ﬁrst round of editing. Next,
the level of evidence was agreed upon by JK, JKe and RB
applying the GRADE system.7 Evidence levels could be
either rated as high, moderate, low or not applicable
(NA). For the statements on the General recommenda-
tions and considerations on clinical study design, ‘Level of
evidence’ was replaced with ‘Grade of recommendation’
(rated with either high, moderate or low). Levels of evi-
dence were not applicable regarding the exclusion crite-
ria. Co-authors were then asked to state their level of
agreement according to the GRADE system in a modi-
ﬁed Delphi process.8, 9 The levels of agreement ranged
from 1 to 6 (1: strongly disagree, 2: disagree with major
reservation, 3: disagree with minor reservation, 4: agree
with major reservation, 5: agree with minor reservation,
6: strongly agree). Authors were asked to provide com-
ments if they disagreed with a statement (rating 3 or
lower).
The answers were treated with conﬁdentiality and
only seen by JK, who did not participate in the voting.
Consensus was deﬁned a priori as agreement (rating 4 or
higher) by at least 75% of the authors. Statements that
achieved more than 75% but less than 90% agreement
were discussed and/or adapted, and rated again in a sec-
ond round. Statements that reached less than 75% con-
sensus after the ﬁrst round were omitted from the
manuscript.
The voting team consisted of those with expertise in
clinical gastroenterology and/or clinical microbiology
with expertise in FMT.
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RECOMMENDATIONS ON CLINICAL APPLICATIONS
(INDICATIONS)
FMT in recurrent C. difﬁcile infection
Key recommendations on FMT in recurrent C. difﬁcile infection
Nowadays, FMT is established as a highly efﬁcient
treatment for recurrent C. difﬁcile infection. FMT is
included in the treatment guidelines for C. difﬁcile
infection provided by the European Society of Clinical
Microbiology and Infectious Diseases, in which it is
strongly recommended for multiple recurrent C. difﬁcile
infection unresponsive to repeated antibiotic treat-
ment.13
Systematic reviews show that FMT treatment for
recurrent C. difﬁcile infection results in cure rates of
about 90%.8, 9, 14–16 So far, the method appears to be
safe and acceptable to the patients.14, 17 The microbiota
changes after FMT in C. difﬁcile infection can persist
over several months. However, more studies evaluating
long-term effects on the microbiota as well as
investigating possible long-term adverse events are
needed.14, 18 Currently, studies are trying to identify
factors determining treatment efﬁcacy and risk of
recurrence.19
The current literature on FMT in C. difﬁcile infec-
tion is mostly based on case reports, case studies and a
number of retrospective studies.15 A randomised clini-
cal trial comparing FMT for treatment of C. difﬁcile
infection to the use of vancomycin alone and to van-
comycin plus bowel lavage was stopped after an
interim analysis, as FMT proved to be much more
effective.20 13 of 16 patients (81%) achieved resolution
of C. difﬁcile infection after FMT via a nasoduodenal
tube, and two of the remaining three achieved resolu-
tion after a second infusion, resulting in an overall suc-
cess rate of 94%. In the patients treated with
vancomycin alone, four of 13 were cured (31%), and
when receiving vancomycin in combination with bowel
lavage, three of 13 (23%) achieved resolution of C. dif-
ﬁcile infection.20 A recent double-blinded, placebo-con-
trolled clinical study found that the administration of
stool from a donor was more efﬁcient than the admin-
istration from the patient’s own stool in achieving reso-
lution (91% vs. 63%) in C. difﬁcile patients (FMT
administered by colonoscopy).21
As the efﬁcacy of FMT in C. difﬁcile infection is
widely accepted nowadays, patients do not necessarily
need to be included in clinical studies. It is advisable
though to include them in a registry and to accurately
report adverse events. If possible, faecal samples from
the patient taken before and after treatment, as well as a
donor sample, should be stored to allow follow-up in
case of adverse events. As such, the ‘American Gastroen-
terological Association (AGA) Fecal Microbiota Trans-
plantation National Registry’ from the AGA Center for
Gut Microbiome Research and Education in the USA
will be launched in the beginning of 2017. Its aim is to
follow-up both short-term as well as long-term adverse
events and safety concerns. A similar registry is already
available in Germany under the name MicroTrans
Registry.22
To avoid the potential risks associated with FMT,
more selective applications of particular forms of
microbes are investigated as potential alternative treat-
ments for FMT in C. difﬁcile. Preliminary results
showed that the oral intake of nontoxigenic C. difﬁcile
spores could reduce C. difﬁcile recurrence.23 In
addition, stool treated with ethanol to eliminate
pathogens and to obtain a puriﬁed fraction of spores
was shown to be effective in preventing C. difﬁcile
recurrence.24
Level of
evidence
Level of
agreement
Patients with recurrent C. difﬁcile
infection with at least two previous
standard treatments without
persistent cure should be
considered for FMT
HIGH 100%
Both standard or family/same
household donors are applicable
HIGH 100%
If possible, patients should be
included in a national registry
NA 100%
Faecal samples from patients before
and after the treatment, if possible,
as well as a donor sample, should
be collected for follow-up in case of
adverse events
NA 100%
So far, it is still unclear if antibiotic
treatment and/or bowel cleansing
before FMT is beneﬁcial or if it
could negatively affect the outcome
(see also ‘Recommendations on
preparation of recipient’)
NA 90%
No speciﬁc route of administration
seems to be preferable regarding
efﬁcacy. However, preliminary data
suggests that application by lower
gastrointestinal tract may be safer
(see also ‘Recommendations on
routes of administration’)
LOW 90%
NA, not applicable.
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FMT in severe and severe-complicated C. difﬁcile
infection
Key recommendations on FMT in severe and severe-compli-
cated C. difﬁcile infection
Increasing clinical challenges in the treatment of
C. difﬁcile infection are severe courses with a consider-
able mortality and recurrence of the infection after suc-
cessful antibiotic treatment. Different deﬁnitions of
severe C. difﬁcile infection are used, and some authors
distinguish fulminant C. difﬁcile infection or severe-com-
plicated C. difﬁcile infection from severe C. difﬁcile
infection as the most serious form of this infec-
tion.13, 25, 26 If antibiotic therapy fails in severe C. difﬁ-
cile infection emergency total colectomy may be
required. Mortality in this situation is very high and
varies between 10% and 80%, mainly depending on the
point of time in the course of disease when surgery is
performed.26, 27
Besides a number of case reports28, 29 smaller, retro-
spective, uncontrolled studies have been published show-
ing that FMT is also effective in treating C. difﬁcile
infection in this clinical situation.30–32 The cure rate was
66–88% with a single FMT and 89–94% if FMT was
repeated in these patients.30–32 Patients with severe-com-
plicated C. difﬁcile infection seem to have a lower primary
response rate to FMT compared to severe C. difﬁcile infec-
tion.30, 32 FMT was applied by different administration
routes, however, colonoscopic FMT was used most
commonly. Some authors continued antimicrobial therapy
against C. difﬁcile infection with vancomycin during and
after FMT in this patient group.32 A recent report suggests
that FMT might be used earlier in patients with the risk of
a severe course. During a ribotype O27 (a C. difﬁcile strain
associated to a more severe disease course) outbreak in
France, the treating physicians changed their treatment
algorithm from use of FMT after at least three relapses to
FMT application in addition to antimicrobial therapy dur-
ing the ﬁrst C. difﬁcile infection episode. Mortality of the
patients dropped from 64% to 19% with the use of the
early FMT treatment approach.33
FMT in inﬂammatory bowel diseases (IBD)
Key recommendations on FMT in IBD
There is increasing evidence that the intestinal micro-
biota play a key role in the aetiopathology of IBD.34 IBD
mouse models do not develop IBD when kept germ-free,35
and both an abnormal, excessive reaction to the commen-
sal gut microbiota or components thereof, or the presence
of one or several pathogens in the intestinal microbiota
evoking an immune reaction are discussed as possible
pathophysiologic mechanisms in IBD.
The intestinal microbiota composition has been shown
to be different in both ulcerative colitis (UC) and
Crohn’s disease (CD), and is generally characterised by a
lower diversity and a decreased stability compared to
healthy controls, which may lead to the loss of normal,
regulatory immune effects of the microbiota.34, 36, 37 It is
Level of
evidence
Level of
agreement
FMT in severe and
severe-complicated C. difﬁcile
infection should be
considered as an alternative
to surgery with total
colectomy in case of early
failure of antimicrobial
therapy
MODERATE 100%
FMT could be considered
already after one treatment
failure
MODERATE 80%
Level of
evidence
Level of
agreement
FMT in IBD should only be
performed in a research setting
NA 100%
If patients with a severely
compromised colon are
considered for FMT, FMT should
be performed with caution as the
risk for side effects is higher and
systematic studies in severe
disease are lacking
LOW 100%
Repeated transfers (possibly via
enemas or capsules) over a
longer time period seem to be
preferable
LOW 90%
Possible donor variations should
be considered
MODERATE 100%
Regarding efﬁcacy, no evidence
for a preferable route is available
for the ﬁrst administration; it
should be chosen according to
the location of the disease and/
or the expertise of the physician.
However, preliminary data
suggests that application by
lower gastrointestinal tract may
be safer (see also
‘Recommendations on routes of
administration’). For repeated
administrations, enemas are
recommended.
LOW 90%
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still unclear if alterations in microbiota composition are
a cause or consequence of the ongoing inﬂammatory
processes, or a combination of both.38–41
A number of case studies showing positive effects of
FMT in IBD have been published.42–49 However, most of
these studies involve low patient numbers, are mostly
published in abstract form, and might be subjected to
publication bias. Results from two controlled clinical
studies have been published to date in full article
form50, 51 and the results of a third one were presented
at the European Crohn’s and Colitis (ECCO) meeting
2016.52
Moayyedi et al. investigated the efﬁcacy of FMT in
active UC (Mayo score ≥4 with an endoscopic Mayo
score ≥1, patients with a disease severity requiring hospi-
talisation were excluded).50 The transplant was provided
as 50 mL enemas once a week for 6 weeks (n = 38).
Water enemas served as placebo (n = 37). At week 7,
remission was achieved in 24% (n = 9) of the patients
that received the microbiota transfer compared to 5%
(n = 2) of the patients that received the placebo. Inter-
estingly, seven of the nine patients in remission after
FMT received stool from the same donor, indicating that
the success rate of stool transfer could be donor-speciﬁc.
In addition, patients with a recent diagnosis of UC
(≤1 year, three of four patients) seemed to respond bet-
ter to the FMT compared to those treated later in the
course of the disease (six of 34 patients). There was a
trend towards patients on immunosuppressant therapy
being more likely to respond to the FMT (5/11, 46%)
than patients without immunosuppressant therapy (4/27
15%, P = 0.09). It needs to be mentioned that in this
study most patients were on TNFa blockers, which
might have introduced a potential bias. In the clinical
study by Rossen et al., the use of TNFa blockers was
prohibited. The authors did not ﬁnd a signiﬁcant differ-
ence for achieving clinical remission between UC
patients receiving faecal transfer (7/23, 30.4%) or their
own stool as a placebo (5/25, 20%).51 The effect of the
placebo (autologous transplant) in this study was rela-
tively high compared to the study by Moayyedi et al. in
which water was used as a placebo. Rossen et al.
included patients with mild to moderate active UC, and
the FMT was performed twice via a nasoduodenal tube
with a 3 weeks interval.
These studies suggest that FMT might be more effec-
tive in mild to moderate IBD, and that repeated treat-
ments over a longer period of time could be superior.
However, more evidence is needed, and data on micro-
biota composition before and after FMT may help to
select patients that could beneﬁt from this treatment.
This is also important for the selection of suitable
donors, as the treatment effect might be donor-
dependent.50, 53
Available evidence suggests that FMT seems to be safe
in IBD patients. However, especially treatment of
patients with a severely compromised colon needs to be
considered carefully, as the risk for side effects is higher
in those patients, and systematic studies in severe disease
are lacking. In addition, case reports have been published
that demand caution in IBD patients. For example, an
altered intestinal permeability could have been the cause
for the onset of bacteraemia with fever after FMT in a
Crohn’s disease patient54 or the new onset of micro-
scopic colitis in an ulcerative colitis patients.55 In one
case, FMT might have induced a severe IBD ﬂare with
extraintestinal manifestations occurring for the ﬁrst time
in a Crohn’s disease patient.56
FMT in IBD with recurrent C. difﬁcile infection
Key recommendations on FMT in IBD with recurrent C. difﬁcile
infection
C. difﬁcile infection is a common comorbidity of IBD.
It is assumed that IBD patients are at higher risk to
develop C. difﬁcile infection compared to non-IBD
patients, and that C. difﬁcile infection is associated with
a higher mortality and more severe outcomes in IBD.57
A decreased microbiota diversity and thereby probably
lower colonisation resistance would explain the higher
risk of C. difﬁcile infection in IBD patients. However, so
far, these assumptions are based on retrospective epi-
demiologic studies prone to selection bias and thus still
remain to be proven.58 To date, prospective studies eval-
uating speciﬁc treatments for C. difﬁcile infection in IBD
have not been published.
A recent retrospective study by Khoruts et al. com-
pared the use of FMT in patients with C. difﬁcile
Level of
evidence
Level of
agreement
Patients with mild to moderate
active IBD with recurrent or
refractory C. difﬁcile infection
should be considered for FMT
MODERATE 100%
Indication needs to be considered
carefully, as ﬂares of IBD activity
have been reported after FMT in
IBD with concurrent C. difﬁcile
infection, as well as a transition
from inactive to active disease in
one case
MODERATE 100%
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infection and IBD to those without IBD, and found a
lower efﬁcacy in clearing the infection in those with
IBD after one FMT (74.4% vs. 92.1%).59 Moreover,
minor IBD ﬂares after FMT for C. difﬁcile infection
have been reported in up to 25% of those patients.59
In a retrospective study by Kelly et al., FMT was
investigated as a treatment for C. difﬁcile infection in
immunocompromised patients, which also included 36
IBD patients on immunosuppressive medication.17 In
this study, resolution of C. difﬁcile infection in the IBD
patients was comparable to previous studies, with resolu-
tion in 86% after a single FMT and 94% including
repeated FMT. IBD ﬂares were experienced by 14% of
the IBD patients after the FMT.
Hamilton et al. performed a study in which the
efﬁcacy of standardised frozen compared to fresh FMT
preparations was evaluated.60 They included 14
C. difﬁcile infection patients, of which n = 4 also suf-
fered from UC, n = 6 from Crohn’s disease and n = 4
from lymphocytic colitis. Independent of using fresh
or frozen preparations, all of these patients
achieved resolution of C. difﬁcile infection after FMT,
and none of these patients experienced IBD ﬂares after
the FMT.
Anderson et al. systematically reviewed case studies,
most of which have been published in abstract form,
which applied FMT for the treatment of recurrent or
refractory C. difﬁcile infection in IBD.61 Outcome data,
which could be obtained for 12 patients, showed a res-
olution of C. difﬁcile infection in 11 of 12 patients, and
improved response to IBD medication in six of seven
patients. Reported adverse events included high fever in
the majority of the patients following FMT, and one
study reported deterioration of UC in two of ﬁve
(moderate to severe chronic active UC, refractory to
standard therapy).62 One case study even reported the
transition from inactive to active UC after FMT in one
patient.63
In conclusion, efﬁcacy of FMT in IBD with C. difﬁcile
infection for resolution of C. difﬁcile infection seems to
be high, but possibly lower than in non-IBD patients.
While most studies conclude that FMT in IBD with
C. difﬁcile infection is safe, some have associated FMT
with deterioration of IBD, particularly in patients with
moderate to severe colitis, but also in patients with
previously quiescent disease. Moreover, side effects have
appeared to be more severe, as seen by the high fever in
some patients, which could be due to impaired barrier
function. Thus, indication needs to be considered
carefully.
FMT in irritable bowel syndrome (IBS)
Key recommendations on FMT in IBS
Irritable bowel syndrome (IBS) is a chronic, functional
gastrointestinal disorder. Although the underlying patho-
physiology is complex and still incompletely understood,
aberrations in the bidirectional gut–brain axis signalling
are generally considered to be a key factor.64 A growing
number of studies demonstrate an aberrant intestinal
microbiota composition in IBS,65–67 and treatments tar-
geting the gut microbiota such as antibiotics, probiotics
and prebiotics can improve IBS symptoms.66, 68–71 A
clear causal link between an aberrant gut ecosystem and
IBS is the development of chronic IBS symptoms after
an enteric infection, the so-called post-infectious IBS.72
Faecal transfer aiming at re-establishing a healthy
intestinal microbiota could be a promising novel treat-
ment option for IBS. To date, only a small number of clin-
ical trials are registered under clinicaltrials.gov, and no
randomised clinical trials investigating the impact of fae-
cal transfer on IBS have been published so far. Only one
study, published as an abstract, reported possible positive
effects in patients with IBS symptoms.73 The same group
Level of
evidence
Level of
agreement
FMT in IBS should only be performed
in a research setting
NA 100%
Primarily IBS patients in whom a
disturbed microbiota seems to be
present should be included in
studies, i.e. patients who:
(i) developed IBS or experienced
deteriorated IBS symptoms
after a gastrointestinal infection
(post-infectious IBS)
(ii) developed IBS or experienced
deteriorated IBS symptoms
after antibiotic treatment
LOW 90%
Preferably IBS patients in whom
standard treatments (such as
dietary changes, smooth muscle
relaxants and reassurance therapy)
have failed should be selected for
studies
LOW 90%
No evidence for a speciﬁc route is
available so far, but administration
of the transplant in the prepared,
right colon, by colonoscopic
procedure, seems preferable
LOW 80%
Placebo-controlled study design is
important as placebo response in
IBS is known to be high (40%)
HIGH 100%
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later applied a mixture of 18 cultured, nonpathogenic bac-
teria resembling normal gut microbiota into the caecum
of IBS patients and reported improved symptoms in 25 of
33 (published as an abstract74).
As the use of FMT in IBS is not evidence-based, it
is important to treat IBS patients with FMT only as
part of clinical studies. In these studies, accurate inclu-
sion criteria, careful characterisation and recording of
medical history of the patients are essential to evaluate
which patients beneﬁt from the offered treatment. In
addition, we recommend to include only patients in
cases where standard treatments (such as dietary
changes, smooth muscle relaxants and reassurance) have
failed. Ideally, an intestinal microbiota analysis should
be performed before and after the treatment, as it may
enable the identiﬁcation of responders on basis of
microbiota composition in combination with other clin-
ical parameters, rather than on basis of symptom-
related sub-classiﬁcation of IBS. If possible, also muco-
sal microbiota should be analysed, as it is likely to have
a large effect on the host due to its close proximity to
the epithelium. In addition, studies have shown that
faecal and mucosal microbiota differ, suggesting that
the faecal microbiota might not be a good surrogate for
the mucosal one.75, 76
Although there is no evidence available for a speciﬁc
route, delivery via colonoscopy, after prior bowel
cleansing, to administer the transplant in the right
colon seems recommendable. The bowel cleansing will
eliminate as much as possible of the present
microbiota.77–79
FMT in metabolic syndrome
Key recommendations on FMT in metabolic syndrome
The intestinal microbiota plays an important role in
metabolising otherwise indigestible food components.
Nonfermentable, complex carbohydrates from plants
reach the colon where they are metabolised by the resi-
dent intestinal microbiota. The main end products are
short-chain fatty acids, mainly butyrate, acetate and pro-
pionate, providing both the microbes themselves as well
as the host with energy.80 It is hypothesised that the
composition of the gut microbiota plays an important
role in the amount of energy harvested from otherwise
undigested food components, and in this way contributes
to the susceptibility for obesity and metabolic syndrome.
An increased capacity for energy harvest has been
demonstrated in studies with germ-free mice trans-
planted with intestinal microbiota from obese mice,
resulting in an increase in total body fat compared to
germ-free mice transplanted with microbiota from lean
mice.81 When fed the same diet, germ-free mice have
40% less total body fat than conventional mice.82
Studies in humans are rare, but there is evidence sug-
gesting an abnormal intestinal microbiota composition in
overweight and obese subjects compared to lean peo-
ple.83–85 Vrieze et al. performed an important study in
which faecal microbiota from healthy lean donors was
transferred into patients with metabolic syndrome.85 The
placebo treatment was an autologous transplant prepared
from the recipient’s own stool. The authors chose to
infuse the transplant into the small intestine, as this is
where most of the carbohydrate and fat uptake occurs,
and due to small-intestinal sensing mechanisms involved
in insulin sensitivity. They found a signiﬁcant increase in
peripheral insulin sensitivity in the recipients of the
donor transplant (n = 9) compared to those of the autol-
ogous transplant (n = 9) which was related to an increase
in butyrate-producing bacteria both in the small intestine
and faeces. Further evaluation of the bacterial strain pop-
ulations in this study suggested that the success of coloni-
sation of newly introduced strains by FMT was higher if
the species were already present in the recipients’ intesti-
nal microbiota.86
Although this study showed promising results, more
trials are needed and FMT in metabolic syndrome should
only be performed in a research setting. Depending on the
disease state, FMT can be hazardous if performed without
adequate precautions, and strict indication and donor
selection needs to be applied. More studies are currently
ongoing and can be found on clinicaltrials.gov. Regarding
the outcome, it is recommended to not only evaluate
weight loss, but also to consider parameters of metabolic
regulation, such as insulin sensitivity and satiety
Level of
evidence
Level of
agreement
FMT in metabolic syndrome should
only be performed in a research
setting
NA 100%
Patients with well-characterised
metabolic syndrome should be
chosen for participation in studies
NA 100%
Regarding the outcome of studies, it is
recommended to not only evaluate
weight loss, but also parameters of
metabolic regulation, such as insulin
sensitivity and satiety hormones
LOW 100%
In studies, careful donor selection
based on predisposition to low body
weight is essential (include family
history)
LOW 100%
228 Aliment Pharmacol Ther 2017; 45: 222–239
ª 2016 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
J. K€onig et al.
hormones. In addition, monitoring of systemic and local
inﬂammatory activity, e.g. via faecal calprotectin and
serum highly sensitive C-reactive protein (CRP), is recom-
mended.
General recommendations and considerations on
clinical study design
Important points to consider when planning clinical
studies using FMT are listed in the following:
Recommendations on clinical study design
METHODOLOGICAL RECOMMENDATIONS
Donor selection
Recommendations on donor selection
The diseases and conditions that should lead to tran-
sient or permanent exclusion of a potential donor are
detailed in Table 1. Tables 2 and 3 show serological and
stool markers that need to be tested to exclude clinically
non-apparent infections.
Potential donors should be screened for infections and
for conditions that may confer an increased risk of
acquisition of infections. Current guidelines recommend
protocols for screening that are similar to those for
blood donors.87–89 Experts agree that potential donors
need to be excluded if they have known HIV infection,
hepatitis B or C virus infection, or known exposure to
these viruses within the previous year.8, 87–90 Hepatitis E
is supposed to be rare and a chronic course of disease is
limited to immunocompromised patients who do not
qualify as stool donors anyway.91 Therefore, hepatitis E
screening is usually not recommended, but subjects with
a known diagnosis should be excluded. Also, subjects
Grade of
recommendation
Level of
agreement
Especially in case of non-
evidence based indications,
faecal and, if possible,
mucosal samples should be
collected from the patients
before and after the
treatment for follow-up of
adverse events and for
identiﬁcation of responders
based on microbiota
composition
(i) Those samples should be
collected before prepar-
ing the colonoscopy with
bowel cleansing and/or
antibiotic treatment
STRONG 100%
Faecal, and, if possible, mucosal
samples from the donors
should be collected to allow
comparison of microbiota
composition between patients
and donors after the FMTand
for follow-up in case of severe
side effects
STRONG 90%
Research on the speciﬁc selection
of a donor on basis of individual
treatment cases (personalised
medicine) is encouraged86
STRONG 100%
‘Professional’ donors instead of
family/same household
donors might be a better
choice regarding
standardisation and
reproducibility as well as
safety screening and cost
efﬁciency
WEAK 90%
The delivery route should be
selected based on the disease
and the location where the
effect is to be achieved (i.e.
immune effect in the small
bowel, microbiota composition
effect in the colon)
STRONG 90%
STATEMENT
Level of
evidence
Level of
agreement
Only healthy adults without acute
or chronic diseases qualify as
stool donors
NA 100%
Donor selection requires exclusion
of diseases and unfavourable
conditions
(i) which have been shown to
be transmitted via blood and pos-
sibly also via FMT
(ii) for which a reasonable pos-
sibility exists that such a transmis-
sion can occur
(iii) in which microbiota is con-
sidered to play a role or which
have been associated with micro-
biota dysbiosis
(iv) which increase probability
of transmission of infections/mul-
tiresistant bacteria and parasites
NA 100%
Donors may be partners, relatives,
friends or unrelated and
previously unknown healthy
subjects (the latter are preferred
for indications in which genetics
play a role, e.g. IBD)
MODERATE 100%
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with Epstein-Barr virus (EBV) and cytomegalovirus
(CMV) should be excluded, especially if the recipients
are negative for those viruses. Some groups also screen
for human T-lymphotropic virus (HTLV). If easily
available, a multiplex PCR detecting further viruses could
be performed (rotavirus, norovirus, enterovirus pare-
chovirus, sapovirus, adenovirus 40/41/52, astrovirus).
Some investigators also perform basic blood analyses
Table 1 | Diseases and circumstances that should lead to (transient or permanent) exclusion of a potential donor for
FMT
Positive history/clinical evidence for
Level of
evidence
IBD or other chronic gastrointestinal diseases including IBS, chronic diarrhoea and chronic constipation 100%
History of or present malignant disease and/or patients who are receiving systemic anti-neoplastic agents 100%
Psychiatric disease (depression, schizophrenia, autism, Asperger’s syndrome) 100%
Chronic neurological/neurodegenerative disease (e.g. Parkinson’s disease; multiple sclerosis) 100%
Autoimmune disease and/or patients receiving immunosuppressive medications 100%
HIV, hepatitis A, B, C or E or known exposure within the recent 12 months 100%
Chronic pain syndromes (e.g. ﬁbromyalgia) 90%
Obesity (BMI > 30), metabolic syndrome 100%
Major relevant allergies (e.g. food allergy, multiple allergies) 90%
Recent (gastrointestinal) infection (within last 6 months) 100%
Travelling in countries with low hygiene or high infection risk for endemic diarrhoea or acquisition
of multiresistant bacteria within the last 6 months
100%
Tattoo or body piercing placement within the last 6 months 100%
Promiscuity 90%
Drug abuse 100%
Antibiotic therapy within the last 3 months 100%
Other chronic use of drugs that may affect the microbiome, e.g. proton pump inhibitors 90%
Table 2 | Serological parameters for infection that should be tested and lead to exclusion if positive
Level of agreement
HIV-1 and -2 100%
Hepatitis A, B, C 90%
Human T-lymphotropic virus (HTLV)* 100%
Syphilis (TPHA) 100%
CMV and EBV (especially if recipient is negative)* 100%
CMV, cytomegalovirus; EBV, Epstein-Barr virus, HIV, human immunodeﬁciency virus.
* Optional, in alignment with the regional and legal situation.
Table 3 | Stool parameters (anal swab) for infection that should be tested and lead to exclusion if positive
Level of agreement
Microscopic examination for ova and parasites (e.g. amoeba) 100%
Infectious bacteria (including enterohaemorrhagic E. coli, salmonella, shigella, yersinia, campylobacter) 100%
Clostridium difﬁcile (GDH screening or PCR) 100%
Multiresistant bacteria (e.g. ESBL producing organisms, MRGN 3 und 4, VRE, MRSA) 100%
Helicobacter pylori (if nasogastric or oral capsules are used for FMT) 90%
Calprotectin >50 mg/kg 80%
ESBL, extended spectrum beta-lactamas; GDH, Glutamate dehydrogenase; MRGN, multiresistant gram-negative bacilli; VRE, van-
comycin-resistant enterococci; MRSA, methicillin-resistant Staphylococcus aureus.
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(full blood count, C-reactive protein, creatinine, liver
enzyme levels) to further exclude undiagnosed relevant
diseases.
Potential donors are also excluded if they participate
in high-risk sexual behaviours, have sexual transmittable
disease, in particular syphilis, use illicit drugs or have
obtained a tattoo or body piercing within the previous
6 months.8 Several studies also exclude subjects who
have been incarcerated. Exclusion of clinically non-
apparent infections requires additional evaluation of
appropriate serological and/or stool parameters (Tables 1
and 2).
Recurrent C. difﬁcile colitis is undoubtedly the main
indication for FMT at present (compare below). Thus, it
is self-evident that toxin producing C. difﬁcile should not
be transferred from the donor and its presence needs to
be excluded (Table 2). Other viral, bacterial or parasitic
gastrointestinal infections that may be associated with
prolonged persistence of the pathogen in the gut of
asymptomatic subjects need to be excluded by laboratory
investigations (Tables 1–3).8, 87–89 Moreover, gastroin-
testinal infections may lead to transient unfavourable
alterations of the microbiota even after elimination of
the pathogen.92 Therefore, stool donation should not be
performed within 6 months after a gastrointestinal infec-
tion.
The same applies to recent antibiotic therapy. Pro-
found alterations of the microbiome occur in response to
antibiotics. Overall normalisation could be seen within
3 months after the end of treatment although subtle dis-
turbances were shown to persist much longer, even after
2 years.93 A high-dose combination therapy, comprising
amoxicillin, tetracycline and metronidazole, induced pro-
found changes of the mucosa-associated microbiota in
patients with ulcerative colitis after 3 months.94 Later
investigations were not performed making it unclear
whether or when “normalisation” of the microbiota
occurs.
There are other drugs that have been shown to
affect the microbiome, in particular proton pump inhi-
bitors (PPIs).95 PPIs are associated with an increased
risk of small bowel bacterial overgrowth.96 It is less
well known but highly likely that they also have an
impact on the colonic microbiota. Several reports
describe an association between PPI administration
and C. difﬁcile infection. However, this was not con-
ﬁrmed in a recent systematic review.97 Thus, it could
be discussed whether chronic use of PPIs should be
an exclusion criterion for stool donors, and, if so, how
long potential donors should abstain from PPI intake
before donation.
Multiresistant bacteria have become a major health
challenge for affected individuals and for the commu-
nity,98 and transmission of multiresistant gut bacteria
during FMT needs to be avoided. The risk of acquir-
ing multiresistant enterobacteria is particularly high if
travelling to the Indian subcontinent (OR 24.8), Asia
(OR 8.63) or Africa north of the equator (OR 4.94).99
However, also in Europe, the prevalence of multiresis-
tant gut bacteria may reach more than 50% and the
EU/EEA population-weighted mean MRSA (Methi-
cillin-resistant Staphylococcus aureus) percentage
remains high at 18% with seven of 30 reporting coun-
tries reporting MRSA percentages above 25%, mainly
in southern and eastern Europe.98 Depending on the
country where the FMT is to be performed it is more
or less feasible to exclude donors who have visited
these countries within the recent 6 months. However,
it is preferable to screen for multiresistant bacteria in
stool and to exclude donors in case of positive ﬁnd-
ings for ESBL (extended spectrum beta-lactamase) pro-
ducing organisms, MRGN (multiresistant Gram-
negative bacilli) 3 and 4, VRE (vancomycin-resistant
enterococci) or MRSA. Remarkably, FMT could reduce
the number of antibiotic-resistant genes in C. difﬁcile
patients.100
During recent years, an increasing number of dis-
eases and health disorders have been shown to be
associated with the composition of the intestinal
microbiota. For most of these conditions causal rela-
tionship is largely unclear. However, given the poten-
tial detrimental long-term effects of FMT, experts
agree that not only subjects with known infections or
increased risks of transmitting infections should be
excluded as stool donors, but also subjects with non-
infectious diseases that have been shown to be trans-
mitted via FMT or for which a reasonable possibility
exists that such a transmission may occur.8, 88–90
Hence, the following diseases and conditions are also
generally regarded as exclusion criteria for potential
stool donors: IBD or other chronic gastrointestinal dis-
orders including IBS, chronic diarrhoea and chronic
constipation, malignant disease/use of cytostatic drugs,
autoimmune disease or use of systemic immunosup-
pressive medication, major allergies, pain syndromes,
obesity (BMI > 30)/metabolic syndrome, psychiatric
disease (e.g. affective disorders, schizophrenia, autistic
spectrum disorder) and chronic neurological/
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neurodegenerative disease (e.g. Parkinson’s disease,
multiple sclerosis).
Given the rigorous exclusion protocol, recruitment of
donors for FMT may be challenging with only a small
proportion of potential donors fulﬁlling all requirements.
Of an unselected group of healthy volunteers replying to
email, newspaper or online advertisements related to an
FMT study and who were able to comply with the
required frequency and duration of donation, approxi-
mately 40% failed to pass the stool screening.101 Thus,
patients who require FMT may not be able to name a
suitable donor, although many physicians and patients
prefer the patients’ own partners, family members and
friends. Intimate contacts (e.g. spouse) have the advan-
tage of shared environmental risk factors minimising the
risk of transmitting an infectious agent.88 Moreover,
maternal-line ﬁrst-degree relatives may have a theoretical
advantage of sharing many microbial species in their
intestinal microbiota with that of the recipient. There-
fore, it is conceivable that the recipient may obtain a
more compatible microbiota derived from such donors.88
On the other hand, there are no studies showing that
material from related donors is better engrafted than
material from unrelated donors, and there is evidence
from blood safety analyses that donors identiﬁed by
patients are more likely to test positive for infectious dis-
ease markers than unrelated volunteer donors.102 More-
over, when FMT is considered to treat diseases in which
genetics play a contributing role, such as IBD, unrelated
donors who do not share the genetic risk may be pre-
ferred.
Many aspects argue in favour of building up a pool of
volunteer donors (or noncommercial stool banks) which
are regularly and thoroughly screened. The optimal
screening frequency is not deﬁned, but should be about
every 3–6 months or more frequently in case of symp-
toms or if changes in risk factors occur, for example,
travelling.
For the purposes of informed consent and a stable
microbiota composition, donors should be at least
18 years of age. There are no data showing that men
should be preferred over women (because of the
higher prevalence of autoimmune disease and IBS in
women) or that it is advantageous to select age- and
sex-matched donors.88 Donors should be asked to
avoid potentially allergic foods such as nuts one week
before donation.
Currently, regulatory authorities in several European
countries103 and the USA104 treat human faeces as a
drug. Exact regulations vary, but the general classiﬁcation
is criticised by several experts as creating a disincentive
for research, restricting access to care, and failing to
evaluate the long-term risks associated with the process.
Instead, classifying stool as a body tissue would be
preferable to address these issues.104
Preparation of stool
Key recommendations on preparation of stool
Studies show that storage conditions of faecal sam-
ples affect the composition of the microbial commu-
nity, although major alterations only occurred after
storage at room temperature for more than
24 h.105, 106 Faecal samples exposed to 80 °C for up
to 6 months also had a stable microbial composi-
tion.106, 107 However, these studies aimed at determin-
ing stability of the microbiome over prolonged periods
of time for subsequent DNA- and RNA-analysis and
this does not necessarily translate into unaltered viabil-
ity of all components. Still, high-throughput DNA
sequence analysis has revealed stable engraftment of
Level of
evidence
Level of
agreement
Fresh stool should be used that
has been evacuated within the
preceding 6 h, in single cases
stool that has been evacuated
within up to 24 h before transfer
may be accepted
LOW 90%
Until further preparation the
evacuated stool should be stored
at 2–8 °C in a hermetically
sealed container
LOW 90%
Alternatively, frozen stool
transplants can be prepared
MODERATE 100%
Depending on the administration
route chosen, the stool needs to
be diluted, homogenised and
ﬁltrated
NA 90%
To avoid vast overgrowth with
aerobic bacteria, the preparation
should be as brief as possible
MODERATE 100%
Stool should be handled according
to legal requirements (e.g.
biosafety level 2 measures) and
adequate gloves and adequate
protective gear should be used
(e.g. facial shields, hood)
NA 100%
The facilities used need to be
cleaned and disinfected using
standards that also effectively
eliminate pathogenic bacteria
(e.g. C. difﬁcile)
NA 100%
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gut microbiota following transfer of previously frozen
faecal bacteria,108 and frozen stool preparations con-
taining glycerol as a preservative, partly encapsulated
for oral application, have been used successfully for
treatment of C. difﬁcile infection.10, 60, 107, 109, 110 These
studies suggest that preparation of frozen transplants
may simplify microbiota transfer without loss of efﬁ-
cacy or safety. On the other hand, commercial distri-
bution of standardised stool preparations could be
subject to legal regulations which could be difﬁcult to
fulﬁl.
Regarding fresh stool, which has been used in the vast
majority of cases, experts recommend to transfer the
sample within 6 h after evacuation.8, 89 Until further
preparation the evacuated stool should be stored at 2–
8 °C in a hermetically sealed container,89 although it is
unclear whether this is absolutely necessary to maintain
high clinical response rates.15
There is no consensus/evidence about the amount of
stool to be used. While smaller amounts (30 g) seem to
be sufﬁcient for treatment of C. difﬁcile infection,10, 60
other researchers/physicians prefer a ‘the more the better
approach’ with up to 200 g of stool per instillation.
Normal saline was used to prepare most FMT sus-
pensions, followed by water and milk.8 Again, there is
no evidence favouring any of the dilutants. On the one
hand, sterile saline is well standardised and less likely
to affect the graft, on the other hand normal stool con-
tains a very low sodium chloride concentration which
might not be physiological for intestinal bacteria. The
required amount varies and depends on stool consis-
tency. Viscosity of the stool suspension should remain
as high as possible to prolong residence time in the gut
of the recipient.89 The donor specimen is homogenised
(using a blender, manual effort or other method) and
usually ﬁltered (e.g. gauze, coffee ﬁlter, strainer). This
processed specimen is then either directly infused into
the gastrointestinal tract or further processed for freez-
ing or production of encapsulated preparations. Proce-
dures are almost always performed under aerobic
conditions although this may affect composition of the
microbiota. To avoid vast overgrowth with aerobic bac-
teria, the preparation should be as brief as possible
and/or the specimen should be cooled (2–8 °C) until
application.89 The use of carbon dioxide during colono-
scopy might reduce the risk of disrupting the anaerobic
environment of the intestine,111 however, no studies
have investigated if using carbon dioxide is more effec-
tive than oxygen.
Route of administration
There is no clear evidence favouring one of the potential
routes of administration and decisions should be based
on the location of the disease in the intestine and the
expertise of the physician. However, upper gastrointest-
inal tract application of FMT has been associated with
more severe side effects than lower gastrointestinal tract
application.
Potential routes of administration are:
(i) Administration into the proximal gastrointestinal
tract via nasogastric, nasoduodenal tube or by endo-
scopic procedure
(ii) Instillation into the proximal colon by endoscopic
procedure
(iii) Rectal or distal colonic administration via enema
(iv) Combined approaches as well as oral application
of encapsulated preparations
A recent systematic review has shown that the major-
ity of adult patients received FMT therapy by colono-
scopy (42.0%), followed by gastric or duodenal
application via a nasogastric or nasoduodenal tube, gas-
troscopy or percutaneous endoscopic gastrostomy (PEG)
(22.7%), enema or retention enemas (12.4%) or combi-
nation of two or more of these methods (11.8%).8 In
8.6%, administration procedure was not reported, and
nasojejunal application was performed in only 2.5% of
patients. Paediatric patients were treated mainly by
enema (45.5%), by nasogastric tube or PEG tube (36.4%)
and less frequently by colonoscopy (18.2%). Colonic
application may appear more physiological and appeal-
ing to the patient and includes prior cleansing of the
bowel which helps to eliminate some of the present
intestinal microbiota.
All routes are highly effective for treatment of recur-
rent C. difﬁcile colitis with a numerical but statistically
nonsigniﬁcant advantage for the colonic applica-
tion.22, 112, 113 Administration via enema is inexpensive
and less invasive than colonic instillation but may be less
effective because enemas usually do not spread beyond
the splenic ﬂexure. Moreover, it may be difﬁcult for
some patients to retain the donor material and com-
monly requires multiple treatments.88 For other indica-
tions, the administration route should be selected based
on the disease and on where in the intestine the trans-
plant effect is to be achieved. For example, in immuno-
logical and metabolic diseases nasogastric or
naosointestinal routes might be preferred, as the small
intestine is much more involved in dietary glucose and
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lipid uptake as well as in training of the innate immune
system.114
However, one needs to be aware of that most severe side
effects associated to the FMT procedure have been
reported with upper gastrointestinal tract application,
which carries some risk of vomiting and aspiration and is
not feasible in patients with severe motility disorders.
Three of four deaths related to FMT occurred after upper
gastrointestinal tract application (two cases of aspiration
pneumonia, one case with sepsis and pneumoperi-
toneum12, 115, 116). In addition, other cases of nonlethal
aspiration pneumonia after vomiting of the faecal suspen-
sion53 and a small bowel abscess have been reported with
nasojejunal application of FMT.51 Patients with IBD fre-
quently show high fever if FMT is applied to the small
bowel.42, 51 In contrast, the one death during lower gas-
trointestinal tract application was caused by aspiration
during sedation for endoscopy which was more related to
the anaesthesia rather than to the FMT itself.17
Whether application by the upper gastrointestinal
tract may also cause small bowel bacterial overgrowth
has not been investigated until now.
Preparation of recipient
Key recommendation on preparation of recipient
In case of caecal administration patients should
undergo normal colonic lavage or other cleansing proce-
dures as routinely used prior to colonoscopy. In case of
oral, transnasal tube placement or gastroscopic proce-
dure, subjects need to be fasted.
Patients undergoing FMT for C. difﬁcile infection typi-
cally receive antibiotic therapy until 1–3 days prior to
the procedure, although it is unclear whether prior
antibiotic therapy to minimise colonisation with patho-
genic C. difﬁcile is effective. If FMT is performed for
non-infectious indications antibiotic therapy is usually
omitted.43 A bowel preparation is usually administered
to patients the day before the transfer to further reduce
C. difﬁcile concentration in the bowel and/or to improve
conditions for colonisation of the donor microbiota in
general. One possible protocol for patient preparation is
an abbreviated regimen of vancomycin (500 mg orally
four times per day for 4 or 5 days), followed by bowel
lavage with 4 litres of macrogol solution on the last day
of antibiotic treatment and the infusion of a suspension
of donor faeces through a nasoduodenal tube.20 Whether
this kind of pre-treatment is required for successful FMT
in C. difﬁcile infection or other potential indications has
not been investigated in controlled trials.
Patients with upper gastrointestinal application, in
particular gastric administration, frequently receive pro-
ton pump inhibitor therapy117 to reduce gastric acidity
that otherwise would compromise the viability of the
transplant. In patients with colonic instillation loperamid
(usually 2–4 mg) may be used to slow down intestinal
transit and to enhance the time for colonisation of donor
bacteria.89
CONCLUSION
FMT is a promising treatment for a variety of diseases in
which the intestinal microbiota is disturbed and it is cur-
rently used as a routine treatment in recurrent C. difﬁcile
infection. For other indications not much evidence from
clinical studies for its efﬁcacy has been obtained so far,
and further investigations are needed before more con-
crete recommendations can be made.
Although FMT has been shown to be a rather safe
method, some severe side effects have been reported, and
its application, especially in diseases with impaired
intestinal barrier functions, can carry risks. These risks
can be limited by systematically and carefully screening
the donor, as described above. In addition, thorough fol-
low-ups are essential to ﬁnd out more about potential
long-term risks and the maintenance of a national regis-
ter is recommended.
An alternative for FMT in the future could be the
so-called synthetic stool that consists of a mixture of
selected beneﬁcial microbial strains.118, 119 It needs to
be kept in mind though that the intestinal microbiota
communities form a very complex ecosystem. The
microbe–microbe interactions and networking play a
pivotal role in the microbe–host interactions, and our
knowledge on this networking is limited. This makes
it difﬁcult to ﬁnd well-deﬁned bacterial strains that are
responsible for speciﬁc effects. Furthermore, the care-
ful handling of strictly anaerobic microbial strains is
very cumbersome yet at the same time a critical factor
with respect to the production of resilient spores.120
Hence, much research remains before an optimal
Level of
evidence
Level of
agreement
Any treatment with antibiotics in
patients who are going to receive
FMT should be stopped in due time
according to the respective
pharmacokinetic properties so that
intracolonic antibiotic concentration
is negligible
LOW 90%
234 Aliment Pharmacol Ther 2017; 45: 222–239
ª 2016 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
J. K€onig et al.
composition of a synthetic stool can be established,
which could circumvent the potential risks associated
with FMT.
There are further indications of FMT that we did not
discuss in this article, as there is no data available, but
might be of interest in the future. One is the preserva-
tion of an individual’s healthy stool before a planned
multiple antibiotic and/or cytostatic treatment. For
example, in certain orthopaedic and urologic cases in
which patients are treated with high doses of antibiotics
over a long period of time, stool could be collected
before, stored frozen and applied by FMT later on in
case problems related to the intestinal microbiota occur.
This could also be an option for multi-antibiotic treat-
ment in infants, which is associated with many risks
such as an increased disposition to develop autoimmune
diseases.121 Exposing infants delivered by caesarean sec-
tion to maternal vaginal ﬂuids and faecal matter to pro-
vide them with a more natural microbiota composition
is also being discussed.
Future studies will hopefully assist in the challenge
to identify patients that beneﬁt from FMT based on
their microbiota composition, as well as to ﬁnd
suitable donors. It seems likely that also immune
effects play an important role in ﬁnding the ‘perfect
match’.
In addition, the impact of diet on improving the
donor’s microbiota as well as maintaining the new
composition in the recipient needs to be investigated.
Diet has clear short-term and long-term effects on the
intestinal microbiota, as shown by comparison between
Western and African populations, human intervention
studies and animal models.80, 122 Future FMT studies
need to take these effects into consideration.
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